Treatment of arthritic disease induced by infectious agents

• US 5,891,865 A
• Filed: 10/04/1996
• Issued: 04/06/1999
• Est. Priority Date: 10/04/1996
• Status: Expired due to Term

• Current Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Original Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Inventors: DeLuca, Hector F., Hayes, Colleen E., Cantorna, Margherita T.
• Primary Examiner(s): Criares, Theodore J.
• Application Number:
  US08/726,894
• Time in Patent Office: 914 Days
• Field of Search: 514/168, 514/167
• US Class Current: 514/167
• CPC Class Codes: A61K 31/59 Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
• CPC Class Codes: A61K 31/592 9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
• CPC Class Codes: A61K 31/593 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis

Abstract

A method of treating arthritis symptoms induced by an infectious agent of an arthritis patient comprising administering to an arthritis patient an amount of vitamin D compound effective to reduce symptoms and observing a reduction in symptoms is disclosed.

Claims

1. A method of treating rheumatoid arthritis or arthritis symptoms induced by infectious agents of an arthritis patient comprising the steps of

administering to a rheumatoid arthritis patient or a patient suffering from arthritis symptoms induced by infectious agents an amount of the following compound effective to reduce arthritis symptoms:

##STR3## wherein X¹ and X² are each selected from the group consisting of hydrogen and acyl;

wherein Y¹ and Y² can be H, or one can be 0=arkyl or 0=alkyl and can have a β

or α

configuration;

Z¹ ═

Z² ═

H or Z¹ and Z² together are CH₂ ; and

wherein R is an alkyl, hydroxyalkyl or fluoroalkyl group, or R may represent the following side chain;

##STR4## wherein (a) may have an S or R configuration, R¹ represents hydrogen, hydroxy or O-acyl, R² and R³ are each selected from the group consisting of alkyl, hydroxyalkyl and fluoralkyl, or, when taken together represent the group-(CH₂),-wherein m is an integer having a value of from 2 to 5, R4 is selected from the group consisting of hydrogen, hydroxy, fluorine, O-acyl, alkyl, hydroxyalkyl and fluoralkyl, wherein if R⁵ is hydroxyl or fluoro, R⁴ must be hydrogen or alkyl, R⁵ is selected from the group consisting of hydrogen, hydroxy, fluorine, alkyl, hydroxyalkyl and fluoroalkyl, or R⁴ and R⁵ taken together represent double-bonded oxygen, R⁶ and R⁷ taken together form a carbon-carbon double bond, R⁸ may be H or CH₃, and wherein n is an integer having a value of from 1 to 5, and wherein the carbon at any one of positions 20, 22, or 23 in the side chain may be replaced by an O, S, or N atom.

2. The method of claim 1 wherein the compound is 1,25(OH)₂ D₃.

3. The method of claim 2 wherein the amount of vitamin D analog administered is between 0.5 and 10 μ

g per day per 160 pound patient.

4. The method of claim 3 wherein the amount of vitamin D analog administered is between 0.5 and 0.75 μ

g per day per 160 pound patient.

5. The method of claim 3 wherein the amount of vitamin D analog administered is between 0.5 and 1.5 μ

g per day per 160 pound person.

6. The method of claim 1 wherein the symptom is joint swelling.

7. The method of claim 1 wherein the compound is selected from the group of 1,25-dihydroxyvitamin D₃, 19-nor-1,25-dihydroxyvitamin D₂, 19-nor-21-epi-1,25-dihydroxyvitamin D₃, 1,25-dihydroxy-24-homo-22-dehydro-22E vitamin D₃, and 19-nor-1,25-dihydroxy-24-homo-22-dehydro-22E-vitamin D₃.

8. The method of claim 1 wherein the amount of compound administered is between 0.5 and 10 μ

g per day per 160 pound patient.

9. The method of claim 1 wherein the amount of compound administered is between 0.5 and 0.75 μ

g per day per 160 pound patient.

10. The method of claim 1 wherein the amount of compound administered is between 0.5 and 1.5 μ

g per day per 160 pound patient.

11. The method of claim 1 wherein the dose is given orally.

12. The method of claim 1 wherein the patient is on a low calcium diet.

13. The method of claim 1 wherein the administering is at night.

14. The method of claim 1, wherein the dose is given orally and wherein the patient is on a low-calcium diet and wherein the dose is 0.5-3.0 μ

g 1,25-dihydroxyvitamin D₃ /day or its analog equivalent.